Ideal for horses with synovitis or early osteoarthritis, before irreversible cartilage damage occurs.
Suitable for cases that show limited response to corticosteroids, hyaluronic acid, IRAP, or other conventional therapies.
Minimal withdrawal considerations make Arthramid® a reliable option for sport horses across all disciplines.
Arthramid® utilizes 2.5% iPAAG technology, originally developed for human osteoarthritis
treatment and now successfully adapted for veterinary use.
This One Health approach bridges advancements in human and animal medicine, ensuring the
highest scientific standards in joint care. Ongoing academic research continues to expand
understanding of iPAAG’s mechanism of action across species.